Alnylam Pharmaceuticals (NASDAQ:ALNY) Given “Buy” Rating at HC Wainwright

Alnylam Pharmaceuticals (NASDAQ:ALNY)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a research report issued on Wednesday,Benzinga reports. They currently have a $510.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price objective would suggest a potential upside of 56.83% from the company’s previous close.

Other equities research analysts have also issued research reports about the company. Wall Street Zen lowered Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday. Canaccord Genuity Group raised their price target on Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the company a “buy” rating in a report on Tuesday, February 17th. Wells Fargo & Company dropped their price target on Alnylam Pharmaceuticals from $479.00 to $376.00 and set an “equal weight” rating for the company in a research report on Tuesday, January 20th. Morgan Stanley decreased their price objective on shares of Alnylam Pharmaceuticals from $495.00 to $408.00 and set an “equal weight” rating on the stock in a research report on Friday, January 30th. Finally, Stifel Nicolaus raised their target price on shares of Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the company a “buy” rating in a research note on Thursday, December 11th. One analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $468.84.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ:ALNY traded up $17.14 during midday trading on Wednesday, reaching $325.19. 494,630 shares of the company traded hands, compared to its average volume of 1,401,456. The firm’s fifty day moving average price is $332.89 and its two-hundred day moving average price is $402.72. The firm has a market capitalization of $43.13 billion, a price-to-earnings ratio of 190.22 and a beta of 0.36. The company has a quick ratio of 2.71, a current ratio of 2.76 and a debt-to-equity ratio of 1.28. Alnylam Pharmaceuticals has a 12 month low of $205.87 and a 12 month high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.18). Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The firm had revenue of $1.10 billion for the quarter, compared to the consensus estimate of $1.16 billion. During the same period last year, the company posted ($0.65) EPS. The business’s revenue was up 84.9% on a year-over-year basis. On average, equities analysts expect that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current year.

Insider Transactions at Alnylam Pharmaceuticals

In related news, EVP Jeffrey V. Poulton sold 2,780 shares of the firm’s stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $362.87, for a total transaction of $1,008,778.60. Following the transaction, the executive vice president directly owned 57,465 shares of the company’s stock, valued at approximately $20,852,324.55. This trade represents a 4.61% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Pushkal Garg sold 2,242 shares of the business’s stock in a transaction that occurred on Friday, February 13th. The stock was sold at an average price of $310.08, for a total value of $695,199.36. Following the completion of the sale, the executive vice president owned 24,848 shares of the company’s stock, valued at $7,704,867.84. The trade was a 8.28% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 53,923 shares of company stock valued at $18,072,087 over the last 90 days. Company insiders own 1.20% of the company’s stock.

Institutional Trading of Alnylam Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the business. OFI Invest Asset Management lifted its stake in shares of Alnylam Pharmaceuticals by 5.8% in the 3rd quarter. OFI Invest Asset Management now owns 403 shares of the biopharmaceutical company’s stock valued at $184,000 after acquiring an additional 22 shares during the last quarter. Howard Capital Management Inc. increased its stake in Alnylam Pharmaceuticals by 2.9% in the 3rd quarter. Howard Capital Management Inc. now owns 854 shares of the biopharmaceutical company’s stock worth $389,000 after purchasing an additional 24 shares during the period. Frank Rimerman Advisors LLC increased its stake in Alnylam Pharmaceuticals by 2.0% in the 3rd quarter. Frank Rimerman Advisors LLC now owns 1,251 shares of the biopharmaceutical company’s stock worth $570,000 after purchasing an additional 24 shares during the period. Coastal Bridge Advisors LLC lifted its position in Alnylam Pharmaceuticals by 2.3% in the third quarter. Coastal Bridge Advisors LLC now owns 1,097 shares of the biopharmaceutical company’s stock valued at $500,000 after purchasing an additional 25 shares during the last quarter. Finally, Meridian Financial Advisors LLC lifted its position in Alnylam Pharmaceuticals by 3.5% in the third quarter. Meridian Financial Advisors LLC now owns 828 shares of the biopharmaceutical company’s stock valued at $378,000 after purchasing an additional 28 shares during the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Needham (Joseph Stringer) reiterated a Buy and kept a $510 price target, citing an underpenetrated TTR market and strong commercial execution that support upside for Alnylam. Alnylam Pharmaceuticals: Underpenetrated TTR Market and Strong Commercial Execution Support Buy Rating
• Positive Sentiment: Bank of America (Tazeen Ahmad) maintained a Buy rating, highlighting durable ATTR growth and momentum for Amvuttra as drivers of near‑term commercial upside. Alnylam Pharmaceuticals: Durable ATTR Growth and Amvuttra Momentum Support Buy Rating and Upside Potential
• Positive Sentiment: Alnylam announced a strategic collaboration with Viz.ai and support for the American Heart Association to accelerate earlier identification and care coordination for ATTR‑CM — a move that could expand diagnosis rates and address the underpenetrated market the analysts reference. Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association
• Positive Sentiment: Coverage notes Alnylam tying AI partnerships to the ATTR‑CM growth and access story — reinforcing the message that diagnostic and digital-health initiatives could drive higher patient identification and ultimately treatment uptake. Alnylam Ties AI Partnerships To ATTR CM Growth And Access Story
• Neutral Sentiment: Transcript coverage (investor/earnings-era discussion) outlines Alnylam’s strategy to transform ATTR care and expand the TTR franchise — useful context but no new clinical or financial data that would immediately move the stock. Alnylam Pharmaceuticals, Inc. (ALNY) Discusses Progress and Strategy in Transforming ATTR Amyloidosis Care and Expanding TTR Franchise Transcript
• Neutral Sentiment: Multiple short‑interest notices in the feed show “significant increase” but report zero shares/NaN values — the data appears erroneous or unreliably reported and shouldn’t be interpreted as meaningful evidence of rising short pressure today.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.